- ISIN
- US03209R1032
- CUSIP
- 03209R103
- Sector
- Healthcare
- IPO Date
- Jun 25, 2014
Highlights
- Market Cap
- $879.21M
- Enterprise Value
- $796.23M
- EPS (TTM)
- $1.68
- PE Ratio
- 11.85
- PEG Ratio
- 0.63
- Total Revenue (TTM)
- $720.53M
- Gross Profit (TTM)
- $341.13M
- EBITDA (TTM)
- $155.96M
- Year Range
- $16.65 - $31.26
- Target Price
- $26.00
- ROA (TTM)
- 4.81%
- ROE (TTM)
- 10.24%
- Avg. Volume (1M)
- 400K
- Avg. Volume Value (1M)
- $7.78M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
AMPH Performance Chart
Amphastar Pharmaceuticals, Inc. (AMPH) is down 25.5% since the beginning of the year. At $20 per share, AMPH is trading 36.2% below its 52-week high of $31. Investors who bought $1,000 worth of AMPH shares 5 years ago would now be looking at an investment worth $952.
Loading charts...
Compare this symbol against anything
Returns By Period
Amphastar Pharmaceuticals, Inc. (AMPH) has returned -25.54% so far this year and -5.99% over the past 12 months. Over the last ten years, AMPH has returned 2.12% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Amphastar Pharmaceuticals, Inc.
- 1D
- -2.16%
- 1M
- 1.53%
- 6M
- -24.73%
- YTD
- -25.54%
- 1Y
- -5.99%
- 3Y*
- -30.98%
- 5Y*
- -0.98%
- 10Y*
- 2.12%
- ALL TIME*
- 9.04%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
AMPH Monthly Returns History
Based on dividend-adjusted daily data since Jun 25, 2014, AMPH's average daily return is +0.07%, while the average monthly return is +1.46%. At this rate, an investment would double in approximately 4.0 years.
Historically, 49% of months were positive and 51% were negative. The best month was Aug 2025 with a return of +46.2%, while the worst month was Feb 2026 at -23.6%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.
On a daily basis, AMPH closed higher 50% of trading days. The best single day was Jun 25, 2014 with a return of +25.0%, while the worst single day was May 10, 2018 at -24.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.08% | -23.63% | -3.16% | 12.10% | -14.16% | 7.06% | -1.19% | -25.54% | |||||
| 2025 | -6.09% | -18.47% | 1.97% | -15.80% | 5.33% | -10.70% | -8.75% | 46.16% | -12.97% | -4.32% | 8.63% | -3.32% | -27.88% |
| 2024 | -13.73% | -12.72% | -5.71% | -6.06% | 2.62% | -5.50% | 8.80% | 11.99% | -0.43% | 4.12% | -10.57% | -17.84% | -39.97% |
| 2023 | 7.99% | 5.29% | 17.70% | -4.61% | 24.04% | 29.52% | 5.60% | -12.16% | -13.73% | -1.57% | 24.41% | 9.82% | 120.74% |
| 2022 | -0.86% | 20.01% | 29.56% | -1.20% | 4.71% | -6.33% | 7.47% | -20.83% | -5.07% | 9.96% | -4.56% | -4.98% | 20.31% |
| 2021 | -9.60% | -3.58% | 4.51% | -5.02% | 8.74% | 6.55% | 3.92% | -6.16% | -3.31% | -1.74% | 4.71% | 19.07% | 15.81% |
Benchmark Metrics
Amphastar Pharmaceuticals, Inc. has an annualized alpha of 9.32%, beta of 0.74, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since June 25, 2014.
- This stock participated in 123.30% of S&P 500 Index downside but only 109.99% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 9.32%
- Beta
- 0.74
- R²
- 0.09
- Upside Capture
- 109.99%
- Downside Capture
- 123.30%
Return for Risk
Risk / Return Rank
AMPH ranks 40 for risk / return — above 40% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Amphastar Pharmaceuticals, Inc. (AMPH) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AMPH | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.50 | ||
| Sortino ratioReturn per unit of downside risk | -1.72 | ||
| Omega ratioGain probability vs. loss probability | 1.04 | 1.25 | -0.21 |
| Calmar ratioReturn relative to maximum drawdown | -0.11 | 2.00 | -2.11 |
| Martin ratioReturn relative to average drawdown | -0.19 | 8.49 | -8.68 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Amphastar Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Amphastar Pharmaceuticals, Inc. was 74.05%, occurring on May 15, 2026. The portfolio has not yet recovered.
The current Amphastar Pharmaceuticals, Inc. drawdown is 69.32%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-74.05%May 2026 | 2y 9mo | — | 2y 12moAug 2023 - now | — |
-49.92%Mar 2020 | 1y 17d | 1y 9mo | 2y 10moMar 2019 - Jan 2022 | COVID crash2020 |
-43.39%Mar 2017 | 3mo 26d | 1y 8mo | 1y 11moNov 2016 - Nov 2018 | — |
-42.11%Feb 2016 | 8mo 8d | 5mo 14d | 1y 1moJun 2015 - Aug 2016 | — |
-35.49%Nov 2022 | 6mo 28d | 5mo 11d | 1y 4dApr 2022 - Apr 2023 | Bear market2022 |
Drawdown Indicators
| AMPH | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.05% | -56.78% | -17.27% |
Max Drawdown (1Y)Largest decline over 1 year | -45.25% | -9.10% | -36.15% |
Max Drawdown (3Y)Largest decline over 3 years | -74.05% | -18.90% | -55.15% |
Max Drawdown (5Y)Largest decline over 5 years | -74.05% | -25.43% | -48.62% |
Max Drawdown (10Y)Largest decline over 10 years | -74.05% | -33.92% | -40.13% |
Current DrawdownCurrent decline from peak | -69.32% | -1.58% | -67.74% |
Average DrawdownAverage peak-to-trough decline | -24.58% | -10.70% | -13.88% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 25.36% | 2.14% | +23.22% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Amphastar Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Amphastar Pharmaceuticals, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for AMPH, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, AMPH has a P/E ratio of 11.9. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for AMPH compared to other companies in the Drug Manufacturers - Specialty & Generic industry. AMPH currently has a PEG ratio of 0.6. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AMPH relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, AMPH has a P/S ratio of 1.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AMPH in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, AMPH has a P/B value of 1.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with AMPH
Add Amphastar Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with AMPH